Jürgen Dinger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jürgen Dinger has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Lothar A. J. Heinemann
Centre for Epidemiology & Health Research Berlin, Invalidenstr. 115, 10115 Berlin, Germany
5 shared publications Thai Do Minh
4 shared publications- Anita Assmann
Centre for Epidemiology & Health Research Berlin, Invalidenstr. 115, 10115 Berlin, Germany
3 shared publications Kristina Bardenheuer
ZEG-Berlin Center for Epidemiology and Health Research, Berlin, Germany
3 shared publications- Do Minh Thai
Centre for Epidemiology & Health Research Berlin, Invalidenstr. 115, 10115 Berlin, Germany
2 shared publications Sabine Möhner
2 shared publications
Latest Publications
- 22 February 2014
- Published by Springer Nature in Die Innere Medizin
- Vol. 55 (3) , 342
Erratum zu: Kardiovaskuläre Auswirkungen hormoneller Kontrazeption
- 22 February 2014
- Published by Springer Nature in Die Innere Medizin
- Vol. 55 (3) , 342
Erratum zu: Kardiovaskuläre Auswirkungen hormoneller Kontrazeption
- 15 November 2013
- Published by Springer Nature in Die Innere Medizin
- Vol. 54 (12) , 1520-1522
Kardiovaskuläre Auswirkungen hormoneller Kontrazeption
- 15 November 2013
- Published by Springer Nature in Die Innere Medizin
- Vol. 54 (12) , 1520-1522
Kardiovaskuläre Auswirkungen hormoneller Kontrazeption
- Open Access
- 29 November 2011
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 38 (1) , 2-6
Combined oral contraceptives, venous thromboembolism, and the problem of interpreting large but incomplete datasets
Subsequently, because of methodological limitations in the Danish study, the European Medicines Agency (EMA) requested a re-analysis. The conduct of the re-analysis was overseen by an independent three-member steering committee [KJ Rothman (Chairman), FE Skjeldestad (nominated by Lidegaard, and a co-author of the published re-analysis)4 and S Shapiro (nominated by Bayer Schering, and a co-author of this commentary)].
- 29 November 2011
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 38 (1) , 2-6
Open AccessCombined oral contraceptives, venous thromboembolism, and the problem of interpreting large but incomplete datasets
Subsequently, because of methodological limitations in the Danish study, the European Medicines Agency (EMA) requested a re-analysis. The conduct of the re-analysis was overseen by an independent three-member steering committee [KJ Rothman (Chairman), FE Skjeldestad (nominated by Lidegaard, and a co-author of the published re-analysis)4 and S Shapiro (nominated by Bayer Schering, and a co-author of this commentary)].
- 1 March 2011
- Published by Elsevier in Contraception
- Vol. 83 (3) , 211-217
Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer
- 1 March 2011
- Published by Elsevier in Contraception
- Vol. 83 (3) , 211-217
Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer
- 1 January 2011
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 117 (1) , 33-40
Effectiveness of Oral Contraceptive Pills in a Large U.S. Cohort Comparing Progestogen and Regimen
To estimate real-life effectiveness of oral contraceptive pills by progestogen, length of pill-free interval, and body mass index while focusing on the effect of progestogens with a long half-life and on 24-day oral contraceptive pills regimens. Outcome data from 52,218 U.S. participants in the International Active Surveillance of Women Taking Oral Contraceptives—a large, prospective, controlled, noninterventional, long-term cohort study with active surveillance of the study participants—were used to analyze contraceptive failure in association with oral contraceptive pills use. Low loss to follow-up is ensured by a comprehensive follow-up procedure. Contraceptive failure rates are described by Pearl Index and life-table analysis. Inferential statistics for contraceptive failure are based on Cox regression models. Analyses are based on 1,634 unintended pregnancies during 73,269 woman-years of oral contraceptive pills exposure. Life-table estimates of contraceptive failure for a 24-day regimen of drospirenone and ethinyl estradiol and 21-day regimens of other progestogens were 2.1% and 3.5% after the first study year, and 4.7% and 6.7% after the third year. The adjusted hazard ratio was 0.7 (95% confidence interval 0.6–0.8). Direct comparisons of the 24-day and 21-day regimens of drospirenone and norethisterone, respectively, showed also lower contraceptive failure rates for 24-day regimens. Contraceptive failure rates adjusted for age, parity and educational level showed a slight increase with higher body mass index. The 24-day oral contraceptive regimens containing a progestogen with a long half-life show higher contraceptive effectiveness under routine medical conditions compared with conventional 21-day regimens. Obesity seems to be associated with a slight reduction of contraceptive effectiveness. ClinicalTrials.gov, www.clinicaltrials.gov, NCT00335257. II
- 1 January 2011
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 117 (1) , 33-40
Effectiveness of Oral Contraceptive Pills in a Large U.S. Cohort Comparing Progestogen and Regimen
To estimate real-life effectiveness of oral contraceptive pills by progestogen, length of pill-free interval, and body mass index while focusing on the effect of progestogens with a long half-life and on 24-day oral contraceptive pills regimens. Outcome data from 52,218 U.S. participants in the International Active Surveillance of Women Taking Oral Contraceptives—a large, prospective, controlled, noninterventional, long-term cohort study with active surveillance of the study participants—were used to analyze contraceptive failure in association with oral contraceptive pills use. Low loss to follow-up is ensured by a comprehensive follow-up procedure. Contraceptive failure rates are described by Pearl Index and life-table analysis. Inferential statistics for contraceptive failure are based on Cox regression models. Analyses are based on 1,634 unintended pregnancies during 73,269 woman-years of oral contraceptive pills exposure. Life-table estimates of contraceptive failure for a 24-day regimen of drospirenone and ethinyl estradiol and 21-day regimens of other progestogens were 2.1% and 3.5% after the first study year, and 4.7% and 6.7% after the third year. The adjusted hazard ratio was 0.7 (95% confidence interval 0.6–0.8). Direct comparisons of the 24-day and 21-day regimens of drospirenone and norethisterone, respectively, showed also lower contraceptive failure rates for 24-day regimens. Contraceptive failure rates adjusted for age, parity and educational level showed a slight increase with higher body mass index. The 24-day oral contraceptive regimens containing a progestogen with a long half-life show higher contraceptive effectiveness under routine medical conditions compared with conventional 21-day regimens. Obesity seems to be associated with a slight reduction of contraceptive effectiveness. ClinicalTrials.gov, www.clinicaltrials.gov, NCT00335257. II
- Open Access
- 1 July 2010
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 36 (3) , 123-129
Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study
Objective: The primary objective of the study was to clarify whether the use of the oral contraceptive 2 mg dienogest/30 μg ethinylestradiol (DNG/EE) is associated with a higher risk of venous thromboembolism (VTE) than the use of other combined oral low-dose contraceptives (i.e. containing ≤30 μg EE), particularly oral contraceptives containing levonorgestrel (LNG). The secondary objective was to investigate the VTE risk associated with drospirenone/ethinylestradiol (DRSP/EE) in comparison to low-dose LNG/EE. Methods: This German community-based, case-control study recruited VTE cases from the primary care sector. Eligible cases were women aged 15–49 years with a VTE between January 2002 and February 2008. Four controls (women without a confirmed or potential VTE before the index date) were matched by age and region to each case. Medical information relevant for the assessment of VTE was abstracted from patient charts. Data on personal characteristics of the patients were collected via self-administered questionnaires. At the end of the study a blinded adjudication of the reported VTE was conducted. Conditional logistic regression techniques were used, adjusting for nine potential confounders, including personal history of VTE, family history of VTE, body mass index, duration of current combined oral contraceptive (COC) use and smoking. Results: A total of 680 VTE cases and 2720 corresponding controls were analysed. The mean age of cases and controls was – as a result of matching – almost identical (36.1 years). A total of 35, 25, and 60 of the cases had used DNG-, DRSP- and LNG-containing low-dose COCs, respectively, at the time of the VTE diagnosis. The crude odds ratio (OR) for VTE associated with current COC use in comparison to women who had never used a COC before the index date was 1.9 (95% CI 1.5–2.5), the adjusted OR was 2.3 (95% CI 1.7–3.0). The point estimate of the crude OR of DNG/EE vs any other low-dose COCs was 0.9 (95% CI 0.6–1.3), the adjusted OR was 0.9 (95% CI 0.6–1.4). The crude ORs for DNG/EE and DRSP/EE vs low-dose LNG/EE were 1.1 (95% CI 0.7–1.8) and 1.0 (95% CI 0.6–1.6), respectively; the adjusted ORs were 1.1 (95% CI 0.7–1.9) and 1.0 (95% CI 0.6–1.8). Conclusions: The study confirms that COC use is associated with an increased risk of VTE. The VTE ORs (adjusted and crude) that compared DNG/EE and DRSP/EE with other low-dose COCs (including LNG/EE) were close to unity and do not indicate a higher risk for users of DNG/EE or DRSP/EE.
- 1 July 2010
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 36 (3) , 123-129
Open AccessRisk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study
Objective: The primary objective of the study was to clarify whether the use of the oral contraceptive 2 mg dienogest/30 μg ethinylestradiol (DNG/EE) is associated with a higher risk of venous thromboembolism (VTE) than the use of other combined oral low-dose contraceptives (i.e. containing ≤30 μg EE), particularly oral contraceptives containing levonorgestrel (LNG). The secondary objective was to investigate the VTE risk associated with drospirenone/ethinylestradiol (DRSP/EE) in comparison to low-dose LNG/EE. Methods: This German community-based, case-control study recruited VTE cases from the primary care sector. Eligible cases were women aged 15–49 years with a VTE between January 2002 and February 2008. Four controls (women without a confirmed or potential VTE before the index date) were matched by age and region to each case. Medical information relevant for the assessment of VTE was abstracted from patient charts. Data on personal characteristics of the patients were collected via self-administered questionnaires. At the end of the study a blinded adjudication of the reported VTE was conducted. Conditional logistic regression techniques were used, adjusting for nine potential confounders, including personal history of VTE, family history of VTE, body mass index, duration of current combined oral contraceptive (COC) use and smoking. Results: A total of 680 VTE cases and 2720 corresponding controls were analysed. The mean age of cases and controls was – as a result of matching – almost identical (36.1 years). A total of 35, 25, and 60 of the cases had used DNG-, DRSP- and LNG-containing low-dose COCs, respectively, at the time of the VTE diagnosis. The crude odds ratio (OR) for VTE associated with current COC use in comparison to women who had never used a COC before the index date was 1.9 (95% CI 1.5–2.5), the adjusted OR was 2.3 (95% CI 1.7–3.0). The point estimate of the crude OR of DNG/EE vs any other low-dose COCs was 0.9 (95% CI 0.6–1.3), the adjusted OR was 0.9 (95% CI 0.6–1.4). The crude ORs for DNG/EE and DRSP/EE vs low-dose LNG/EE were 1.1 (95% CI 0.7–1.8) and 1.0 (95% CI 0.6–1.6), respectively; the adjusted ORs were 1.1 (95% CI 0.7–1.9) and 1.0 (95% CI 0.6–1.8). Conclusions: The study confirms that COC use is associated with an increased risk of VTE. The VTE ORs (adjusted and crude) that compared DNG/EE and DRSP/EE with other low-dose COCs (including LNG/EE) were close to unity and do not indicate a higher risk for users of DNG/EE or DRSP/EE.
- Open Access
- 18 November 2009
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 9 (1) , 77
International Active Surveillance Study of Women Taking Oral Contraceptives (INAS-OC Study)
A 24-day regimen of contraceptive doses of drospirenone and ethinylestradiol (DRSP/EE 24d) was recently launched. This regimen has properties which may be beneficial for certain user populations (e.g., women suffering from premenstrual dysphoric disorder or acne). However, it is unknown whether this extended regimen has an impact on the cardiovascular risk associated with the use of oral contraceptives (OCs). The INternational Active Surveillance study of women taking Oral Contraceptives (INAS-OC) is designed to investigate the short- and long-term safety of the new regimen in a population which is representative for the typical user of oral contraceptives.
- 18 November 2009
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 9 (1) , 77
Open AccessInternational Active Surveillance Study of Women Taking Oral Contraceptives (INAS-OC Study)
A 24-day regimen of contraceptive doses of drospirenone and ethinylestradiol (DRSP/EE 24d) was recently launched. This regimen has properties which may be beneficial for certain user populations (e.g., women suffering from premenstrual dysphoric disorder or acne). However, it is unknown whether this extended regimen has an impact on the cardiovascular risk associated with the use of oral contraceptives (OCs). The INternational Active Surveillance study of women taking Oral Contraceptives (INAS-OC) is designed to investigate the short- and long-term safety of the new regimen in a population which is representative for the typical user of oral contraceptives.
- Open Access
- 1 October 2009
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 35 (4) , 211-213
Oral contraceptives and venous thromboembolism: old questions revisited
- 1 October 2009
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 35 (4) , 211-213
Open AccessOral contraceptives and venous thromboembolism: old questions revisited
- 1 September 2009
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 201 (3) , 263.e1-263.e9
Oral contraceptive effectiveness according to body mass index, weight, age, and other factors
- 1 September 2009
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 201 (3) , 263.e1-263.e9
Oral contraceptive effectiveness according to body mass index, weight, age, and other factors